Researchers at The University of Dundee in Scotland, UK are set to lead a clinical trial of Insmed’s brensocatib (formerly INS1007) for the treatment of Covid-19 patients.
Insmed will provide funding and supply the drug, which is being developed to treat lung inflammation in bronchiectasis and other inflammatory conditions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new trial, called STOP-COVID19, will assess the drug’s ability to decrease the incidence of acute lung injury and prevent mechanical ventilation in up to 300 hospitalised patients at ten sites across the UK.
